{"id":2427,"date":"2014-01-02T16:15:01","date_gmt":"2014-01-02T21:15:01","guid":{"rendered":"https:\/\/www.med.unc.edu\/htcenter\/tretten-approved-for-rare-genetic-clotting-disorder\/"},"modified":"2022-09-28T15:31:47","modified_gmt":"2022-09-28T19:31:47","slug":"tretten-approved-for-rare-genetic-clotting-disorder","status":"publish","type":"post","link":"https:\/\/www.med.unc.edu\/htcenter\/tretten-approved-for-rare-genetic-clotting-disorder\/","title":{"rendered":"Tretten approved for rare genetic clotting disorder"},"content":{"rendered":"<p class=\"lead\">On December 23, the U.S. Food and Drug Administration approved Tretten (coagulation factor XIII A-subunit [recombinant]) for use in the routine prevention of bleeding in adults and children who have congenital Factor XIII A-subunit deficiency, a rare clotting disorder.<\/p>\n<div>\n<p>Tretten is a recombinant analog of the human Factor XIII A-subunit that is produced in yeast cells and then further purified. It is a sterile freeze-dried powder that is reconstituted for IV administration.<\/p>\n<p>The efficacy of Tretten was evaluated in a Phase 3 trial that enrolled 77 patients with congenital Factor XIII A-subunit deficiency. Treatment with Tretten prevented bleeding in 90% of the patients when administered monthly. Tretten is expected to be available in early 2014 from Novo Nordisk, Inc.<\/p>\n<p>See the FDA press release <a class=\"external-link\" title=\"\" href=\"http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm379696.htm\" target=\"_self\" rel=\"noopener noreferrer\">here<\/a>.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>On December 23, the U.S. Food and Drug Administration approved Tretten (coagulation factor XIII A-subunit [recombinant]) for use in the routine prevention of bleeding in adults and children who have congenital Factor XIII A-subunit deficiency, a rare clotting disorder.<\/p>\n","protected":false},"author":38607,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[1],"tags":[],"class_list":["post-2427","post","type-post","status-publish","format-standard","hentry","category-news","odd"],"acf":[],"featured_image":false,"featured_image_medium":false,"featured_image_medium_large":false,"featured_image_large":false,"featured_image_thumbnail":false,"featured_image_alt":false,"category_details":[{"name":"HTC News","link":"https:\/\/www.med.unc.edu\/htcenter\/category\/news\/"}],"tag_details":[],"_links_to":[],"_links_to_target":[],"_links":{"self":[{"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/posts\/2427","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/users\/38607"}],"replies":[{"embeddable":true,"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/comments?post=2427"}],"version-history":[{"count":0,"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/posts\/2427\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/media?parent=2427"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/categories?post=2427"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.med.unc.edu\/htcenter\/wp-json\/wp\/v2\/tags?post=2427"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}